Abstract
Direct‐to‐consumer genetic testing is an unavoidable consequence of our ability to cheaply and accurately measure the genome. Some are troubled by the loss of control over how and when this information is disclosed to individuals, but it is difficult to imagine any way to prevent the wide availability of these data. Therefore, the key challenge is to set up social, educational, and technical means to support individuals who have access to their genome. Clinical Pharmacology & Therapeutics (2009); 86 , 1, 15–17 doi:10.1038/clpt.2009.63